Does the Systemic Immune-Inflammation Index predict lymph node metastasis in Thyroid Cancer?
The Systemic Immune-Inflammation Index (SII) is a blood test that combines counts of neutrophils, platelets, and lymphocytes. It reflects the body's immune and inflammatory state. Several studies have looked at whether SII can predict if thyroid cancer has spread to lymph nodes. The evidence suggests that higher SII levels are linked to a greater chance of lymph node metastasis, but the test is not perfect and works best alongside other factors like tumor size.
What the research says
A 2022 study of 713 patients with papillary thyroid cancer found that a higher preoperative SII was an independent risk factor for lateral lymph node metastasis (spread to lymph nodes in the side of the neck). The model that included SII and tumor diameter had an area under the curve (AUC) of 0.860, meaning it correctly identified patients with metastasis about 86% of the time 6. A 2026 study using machine learning on 1,697 patients also identified SII as one of the top predictors for central lymph node metastasis (lymph nodes near the thyroid), with a stacking ensemble model achieving an AUC of 0.923 in validation 7.
A systematic review and meta-analysis of 10 studies (including 2,209 participants for diagnostic accuracy) found that SII had a pooled sensitivity of 76.8% and specificity of 71.2% for detecting thyroid cancer, and an AUC of 0.805. In a separate analysis of 5 studies (2,073 participants), patients with lymph node metastasis had significantly higher SII levels than those without 2.
However, not all studies show a strong link. A 2023 study of 75 patients with medullary thyroid cancer found that while higher SII was associated with more advanced disease, only the neutrophil-to-lymphocyte ratio (NLR) was significantly linked to lymph node metastasis in univariate analysis; SII was not an independent predictor in multivariate analysis 8. This suggests that SII's predictive value may vary by thyroid cancer type.
Overall, SII is a promising, low-cost tool that can help assess lymph node metastasis risk, but it should be used together with other clinical and imaging findings, not alone.
What to ask your doctor
- What is my SII level, and how does it compare to levels linked to lymph node metastasis?
- Should SII be used along with other tests like ultrasound or tumor markers to assess my risk?
- Does my type of thyroid cancer (papillary, medullary, etc.) affect how useful SII is for predicting spread?
- If my SII is high, what additional steps might be needed to check for lymph node involvement?
- Are there other blood-based inflammation scores (like NLR or PLR) that might be more relevant for my case?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.